These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17691918)

  • 1. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: evidences and potential implications.
    Zsila F
    Curr Drug Metab; 2007 Aug; 8(6):563-93. PubMed ID: 17691918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
    Breier A; Barancík M; Sulová Z; Uhrík B
    Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.
    Mora Lagares L; Minovski N; Caballero Alfonso AY; Benfenati E; Wellens S; Culot M; Gosselet F; Novič M
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(p-azido-3-[125I]iodophenethyl)spiperone binds to specific regions of P-glycoprotein and another multidrug binding protein, spiperophilin, in human neuroblastoma cells.
    Safa AR; Agresti M; Bryk D; Tamai I
    Biochemistry; 1994 Jan; 33(1):256-65. PubMed ID: 7904476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
    Bansal T; Jaggi M; Khar RK; Talegaonkar S
    J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting binding to p-glycoprotein by flexible receptor docking.
    Dolghih E; Bryant C; Renslo AR; Jacobson MP
    PLoS Comput Biol; 2011 Jun; 7(6):e1002083. PubMed ID: 21731480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment.
    Waghray D; Zhang Q
    J Med Chem; 2018 Jun; 61(12):5108-5121. PubMed ID: 29251920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychotropic drug-drug interactions involving P-glycoprotein.
    Akamine Y; Yasui-Furukori N; Ieiri I; Uno T
    CNS Drugs; 2012 Nov; 26(11):959-73. PubMed ID: 23023659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
    Zhou SF
    Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting P-glycoprotein-mediated drug transport based on support vector machine and three-dimensional crystal structure of P-glycoprotein.
    Bikadi Z; Hazai I; Malik D; Jemnitz K; Veres Z; Hari P; Ni Z; Loo TW; Clarke DM; Hazai E; Mao Q
    PLoS One; 2011; 6(10):e25815. PubMed ID: 21991360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavonoids as P-gp Inhibitors: A Systematic Review of SARs.
    Cui J; Liu X; Chow LMC
    Curr Med Chem; 2019; 26(25):4799-4831. PubMed ID: 30277144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1).
    He SM; Li R; Kanwar JR; Zhou SF
    Curr Med Chem; 2011; 18(3):439-81. PubMed ID: 21143116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
    Watanabe T; Uchiyama N; Roninson IB; Cohen D; Atadja P
    Int J Oncol; 2000 Sep; 17(3):579-86. PubMed ID: 10938401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The P-glycoprotein multidrug transporter.
    Fardel O; Lecureur V; Guillouzo A
    Gen Pharmacol; 1996 Dec; 27(8):1283-91. PubMed ID: 9304397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological strategies for overcoming multidrug resistance.
    Nobili S; Landini I; Giglioni B; Mini E
    Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance.
    Qiu Q; Shi W; Li Z; Zhang B; Pan M; Cui J; Dai Y; Huang W; Qian H
    J Med Chem; 2017 Apr; 60(7):2930-2943. PubMed ID: 28301155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
    Crivori P; Reinach B; Pezzetta D; Poggesi I
    Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.